Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Development and Situation of Radionuclide Imaging and Therapy in Oncology

Development of nuclear medicine in oncology

Prospect and Status of PET Radiopharmaceuticals in Oncology

Clinical Application of Radionuclide Imaging and Radiotherapy in Skeletal and Soft Tissue Tumors

Advances in Radionuclide Molecular Imaging and Targeting Therapy in Lymphoma

Prospective of New Technique Application in Nuclear Oncology

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors.

Radiolabeled PET/MRI Nanoparticles for Tumor Imaging

Recent Advances in Molecular Image-Guided Cancer Radionuclide Therapy.

Molecular Imaging and Therapy of Cancer with Radiolabeled Nanoparticles.

Advances on interventional molecular imaging

Application Study on Isotope Tracing RRL Tumor Angiogenesis Imaging

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Development of Study on SPECT Imaging with Radioisotope 99Tcm-Octreotide

Progress on radionuclide-labeled small peptides in targeting tumor angiogenesis

Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview

Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET

Development of Rgd-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside

Progress and prospect of molecular probes of radionuclide tracing targeted tumor angiogenesis

The Current Status and Future Directions on Nanoparticles for Tumor Molecular Imaging

Application of Radionuclide Tracing Technique on the Diagnosis and Treatment for Diseases